Clinical trials: Thrombocytopaenia
Systemic Lupus Erythematosus, Immune Thrombocytopenia
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
The goal of this clinical trial is to learn if sirolimus, added to standard background therapy (corticosteroids and hydroxychloroquine), works to treat systemic lupus erythematosus-associated immune thrombocytopenia (SLE-ITP) in…
- Trial name
- NCT07657793
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Chinese SLE Treatment And Research Group
Extracorporeal Circulation; Complications, Coagulation Disorder
Impact of Cardiac Surgery With a Minimal Invasive Extracorporeal Circuit οn Coagulation: Data From Point of Care Devices
This study includes patients undergoing elective cardiac surgery on MiECC. Coagulation status is assessed with ROTEM (TEM International GmbH, Munich, Germany) and Platelet function with impedance aggregometry using the…
- Conditions
- Extracorporeal Circulation; Complications, Coagulation Disorder, Extracorporeal Circulation of Blood; Thrombocytopenia
- Trial name
- NCT04159064
- Testing
- Thromboelastometry, Impedance Aggregometry
- Where
- Greece
- Volunteers
- 57 people
- Sponsor
- AHEPA University Hospital
Immune Thrombocytopenic Purpura
Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)
This trial is designed as a multi-centre, single-dose, exploratory dose-finding, open label trial evaluating the safety and efficacy of Sym001 in 4-9 consecutive cohorts. Subjects will receive a single IV dose of Sym001.
- Trial name
- NCT00718692
- Testing
- Sym001
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 61 people
- Sponsor
- Symphogen A/S
Severe Aplastic Anemia
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
Background: Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells.
- Trial name
- NCT04304820
- Testing
- Eltrombopag, Cyclosporine, Horse-Anti-thymocyte-Globulin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Immune Thrombocytopenia, Treatment
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of primary immune thrombocytopenia in patients who have failed first-line treatment.
- Trial name
- NCT06838962
- Testing
- Daratumumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
This protocol will provide open label romiplostim to adult thrombocytopenic subjects. Romiplostim will be administered by subcutaneous injection once per week.
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenic Purpura
- Trial name
- NCT00508820
- Testing
- Romiplostim
- Volunteers
- 407 people
- Sponsor
- Amgen
ITP - Immune Thrombocytopenic Purpura, Viral Hepatitis
Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy
Aim of the work To estimate frequency of viral HB \& C infection in ITP patients who received triple therapy in comparison with another group treated with steroids only.
- Trial name
- NCT04113915
- Testing
- triple therapy, Steroids
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Safaa AA Khaled
Thrombocytopenia, Hepatitis C
Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C
This study will provide chronic hepatitis C patients with low platelets (less than 75x10^9/L) the opportunity to undergo treatment and possible cure of their virus.
- Trial name
- SQUELCH-C (NCT01821625)
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Immune Thrombocytopenia
The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of Upadacitinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune…
- Trial name
- NCT07064889
- Testing
- Dexamethasone, Upadacitinib
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Peking University People's Hospital
Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
This single-arm, open-label exploratory trial aims to evaluate the safety, feasibility, and preliminary efficacy of RN1201 Injection in patients with antibody-mediated diseases, including refractory immune-mediated platelet…
- Trial name
- NCT07072247
- Testing
- CD19 and BCMA-targeted allogeneic CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Immune Thrombocytopenia
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsule plus high-dose dexamethasone for the treatment of…
- Trial name
- NCT05023915
- Testing
- dexamethasone, diammonium glycyrrhizinate enteric-coated capsule
- Where
- 2 sites in China
- Volunteers
- 106 people
- Sponsor
- Shandong University
Immune Thrombocytopenia
A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013
This is a retrospective analysis of children (≤21years old) who received clinical treatment with either Romiplostim or Eltrombopag at 2 medical centers from 2009-2013.
- Trial name
- NCT01974232
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Weill Medical College of Cornell University
Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenic Purpura
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines.
- Trial name
- NCT01713855
- Testing
- Inactivated Trivalent Influenza vaccine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Neufeld, Ellis J, MD, PhD
Thrombotic Microangiopathy
Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients
Thrombotic Microangiopathy (TMA) Associated with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a serious complication that is associated with increased morbidity, related to multiple organ failure, with increased…
- Trial name
- NCT07059026
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- ITAC (Instituto de Trasplantes y Alta Complejidad)
Thrombocytopenia, Hepatitis C
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Thrombocytopenia occurs when a person's blood has a decreased number of platelets, which are cells involved in blood clotting. This condition may lead to uncontrolled bleeding and can be fatal.
- Conditions
- Thrombocytopenia, Hepatitis C, HIV Infections
- Trial name
- NCT00239733
- Testing
- Anti-D
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Thrombocytopenia
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
Individuals with immune thrombocytopenia (ITP) frequently report difficulties with attention and memory. The main question this study seeks to answer is: Do patients with ITP have evidence of cognitive impairment as detected by a…
- Trial name
- COGFIT (NCT06817395)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL).
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- PACIFICA (NCT03165734)
- Testing
- Pacritinib, Physician's Choice medications
- Where
- 207 sites in United States, Australia and 22 more
- Volunteers
- 407 people
- Sponsor
- Swedish Orphan Biovitrum
Thrombocytopaenia
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or…
- Trial name
- NCT01147809
- Testing
- Eltrombopag olamine
- Where
- 86 sites in United States, Belgium and 11 more
- Volunteers
- 130 people
- Sponsor
- GlaxoSmithKline
Thrombocytopenia, Avatrombopag
Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia
To evaluate the efficacy and safety of Avatrombopag in patients with thrombocytopenia induced by targeted therapy and immunotherapy combination treatment, and provide evidence-based medication for the clinical use of Avatrombopag…
- Trial name
- NCT04896528
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- PAC326 (NCT02055781)
- Testing
- Pacritinib, Best Available Therapy
- Where
- 122 sites in United States, Australia and 10 more
- Volunteers
- 311 people
- Sponsor
- CTI BioPharma